Common AEs Following Treatment With Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone

Pharmacy Times^® interviewed Suzanne Trudel, MD, MSC, FRCPC, an associate professor at the University of Toronto and a consultant in the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre in Toronto, on one of her presentations at the 62^nd ASH Annual Meeting and Exposition. The presentation is on the part 1 results of a dose finding study of belantamab mafodotin (belamaf) in combination with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM).

In this video, Trudel discusses the common adverse events observed in patients with RRMM following treatment with belamaf in combination with pomalidomide and dexamethasone.